Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    DARPA Brings Down the HAMMER on Malaria

    By Global Biodefense StaffMay 25, 2016
    THOR's HAMMER - Technologies for Host Resilience
    Illustration credit: Alexa F. Volpe
    Share
    Facebook LinkedIn Reddit Email
    THOR's HAMMER - Technologies for Host Resilience
    Illustration credit: Alexa F. Volpe

    The Defense Advanced Research Projects Agency (DARPA) and the Army Research Laboratory (ARL) are supporting an international research collaboration with a $6.4 million contract to investigate the mechanisms behind “resilience” following malaria infection.

    The research partnership is part of DARPA’s Technologies for Host Resilience (THoR) program and is termed the Host Acute Models of Malaria to study Experimental Resilience (HAMMER) project.

    HAMMER is one of a several projects in the THoR program, established for a three-year period, covering a variety of diverse host-pathogen model systems. The HAMMER project uniquely focuses on malaria and its effects on human and non-human primate hosts.

    Researchers at Emory University, the University of Georgia, and the Georgia Institute of Technology, along with national and international collaborators, will work to identify host features associated with resilience, thinking beyond the host’s immune response into the realms of physiology, biochemistry and pathogenesis, and develop interventions that could enhance that resilience.

    The investigators believe learning why malaria causes acute, potentially lethal disease in some humans and animals, while others are much more resilient or tolerant, could lead them to better intervention strategies for malaria and other diseases, including new and better drugs.

    Malaria, which is transmitted through mosquito bites, is the most widespread human parasitic disease and is endemic in approximately 100 countries. It causes fever, pain and other acute responses, and in severe cases it can become deadly within days of the onset of symptoms.

    “Malaria is a potentially lethal disease, but resilience in some people and non-human primates allows them to control the disease and avoid adverse outcomes, so that the infection is not incapacitating,” says Mary R. Galinski, Ph.D., professor of medicine and infectious diseases at Emory University School of Medicine, Emory Vaccine Center and Yerkes National Primate Research Center.

    Read more: DARPA’s Biotechnology EZ BAA Streamlines Proposal Process

    In addition to Galinski, key leaders of the THoR HAMMER project include Juan B. Gutierrez, Ph.D., associate professor of mathematics and bioinformatics at the University of Georgia, and Rabindra Tirouvanziam, Ph.D., assistant professor of pediatrics at Emory University School of Medicine. The project includes more than 40 established investigators in infectious diseases, systems biology, physiology, pathology, immunology, genomics, bioinformatics, pediatrics, cardiology, pulmonology, biomedical engineering, and mathematics at the three institutions, and through other collaborations.

    THoR’s HAMMER project focuses on the malaria parasite Plasmodium knowlesi, which can infect both humans and non-human primates. Plasmodium knowlesi causes mild chronic infections in some monkeys, such as long-tailed and pig-tailed macaques, which are its natural hosts. However, it causes severe, virulent infections in other monkeys, such as rhesus macaques.

    Using systems biology approaches, the THoR’s HAMMER team will generate large datasets on characteristics of P. knowlesi infection in the two types of non-human primates and in humans. They will then develop and apply mathematical models to compare and contrast the different scenarios of infection to identify particular host features associated with resilience. This may yield insights that could lead to novel interventions for malaria, including new drugs.

    The researchers will use surgically implanted telemetry devices to gather continuous real-time physiological data from the two types of monkeys, before and during infection, including temperature, heart rate, blood pressure, and mobility. The HAMMER project will investigate correlates of physiological signals captured via telemetry with clinical and molecular variables, to detect signatures of the onset of severe disease.

    The team also is collaborating with Balbir Singh, professor and director of the Malaria Research Centre at the University of Malaysia, Sarawak, to examine a large cohort of samples from human P. knowlesi infections. Malaysian Borneo is the epicenter of a significant animal-to-human public health threat in Southeast Asian countries and P. knowlesi accounts for the majority of Borneo’s malaria cases. Such zoonotic infections have been reported in other parts of Malaysia, the Philippines, Thailand, Cambodia, Myanmar and Vietnam.

    “By combining the new technology of telemetry devices in non-human primates with data from human infections, our project will both deepen understanding of malaria caused by P. knowlesi, and generate valuable information to address other types of malaria, including disease caused by P. falciparum and P. vivax, the most common malaria parasites worldwide,” says Gutierrez.

    Read more: DARPA INTERCEPT Program for Biodefense Countermeasures

    The researchers’ ultimate goal is to test candidate therapeutic interventions in highly susceptible hosts with the aim of reducing disease severity and death in the absence of effective antimalarial chemotherapy, or in conjunction with antimalarial chemotherapy. If successful, such host-directed therapeutic strategies could be available for use by people in need, whether they are infected with P. knowlesi, other species of Plasmodium, and possibly other pathogens. These challenging goals are fitting with DARPA’s track record taking on some of the world’s most difficult and creative research projects, venturing into unchartered scientific territory.

    The THoR’s HAMMER project builds upon the scientific infrastructure of the Malaria Host-Pathogen Interaction Center (MaHPIC), a malaria systems biology partnership between Emory, UGA, Georgia Tech, and the CDC Foundation, established in 2012.

    Through its robust, multi-institutional research partnership and global collaborations, MaHPIC has used technological advances to conduct innovative systems biology research in non-human primates and applied mathematical modeling tools to integrate large, diverse datasets, including from human samples. The MaHPIC and HAMMER team members will work collaboratively to further the distinct goals of both projects.

    “Our systems biology team, which has become well-established through our MaHPIC consortium, plans to positively impact the work of all THoR projects by continuing to promote cross-fertilization of ideas both within our team and among all THoR project participants nationally,” says Tirouvanziam.

    Animal Models Bioinformatics DARPA Immune Response Malaria
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleFDA Approves First Quadrivalent Cell Culture-Based Flu Vaccine
    Next Article Fishing for Phages to Treat Dangerous Infections

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy